Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Double-Blind, Controlled Trial to Assess the Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Subjects Aged Between 2 and <18 Years and Living in Dengue Endemic Countries in Asia and Latin America

NCT02302066 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT02302066
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02302066 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Double-Blind, Controlled Trial to Assess the Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Subjects Aged Between 2 and <18 Years and Living in Dengue Endemic Countries in Asia and Latin America
Lead sponsor
Takeda
Phase
Phase 2
Overall status
Completed
Start date
December 5, 2014
Completion date
February 18, 2019
Enrollment
1,800 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

dengue fever